Abeona Therapeutics
Biotechnology, 1330 Ave of the Americas Fl 33, New York, 10019, United States, 51-200 Employees
Phone Number: 21********
Who is ABEONA THERAPEUTICS
Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Companys multi-platform exp...
Read More
-
Headquarters: 1330 Ave of the Americas Fl 33, New York, New York, 10019, United States
-
Date Founded: 2015
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
-
CEO:
Charlotte Chambers
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ABEONA THERAPEUTICS
Abeona Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Abeona Therapeutics
Answer: Abeona Therapeutics's headquarters are located at 1330 Ave of the Americas Fl 33, New York, 10019, United States
Answer: Abeona Therapeutics's phone number is 21********
Answer: Abeona Therapeutics's official website is https://abeonatherapeutics.com
Answer: Abeona Therapeutics's revenue is $25 Million to $50 Million
Answer: Abeona Therapeutics's SIC: 2834
Answer: Abeona Therapeutics's NAICS: 325412
Answer: Abeona Therapeutics has 51-200 employees
Answer: Abeona Therapeutics is in Biotechnology
Answer: Abeona Therapeutics contact info: Phone number: 21******** Website: https://abeonatherapeutics.com
Answer: Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Companys multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Companys robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIMTM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month